---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-036875"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:11:14.669874+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst completes sale of European ORLADEYO business; receives $250M upfront

## Summary
- Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.
- Transaction valued at ~5.4x trailing 12-month European ORLADEYO sales (through June 2025).
- Will use proceeds to retire $199M Pharmakon term loan, strengthening balance sheet.
- Reaffirms FY2025 revenue guidance of $580M–$600M, expects upper half excluding European revenue.
- European business was approximately breakeven; divestiture improves operating margin and focuses on U.S. core.

## SEC filing metadata
- accession: 0001140361-25-036875
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/0001140361-25-036875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-036875
- JSON: https://secwatch.observer/filing/0001140361-25-036875.json
- Plain text: https://secwatch.observer/filing/0001140361-25-036875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.